GlassScriptPhysician profile
Daniel S Pacifico
NPI 1497868731
$3,201.33
in general payments reported to CMS, 2019-2025
27 companies · $814 in 2025
The $814 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $97.03 · 2021: $146 · 2022: $414 · 2023: $579 · 2024: $557 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,950.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $874.16 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $385.88 | 2019-2024 | Xarelto |
| Pfizer INC. | $335.93 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $307.89 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $277.65 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $274.07 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $98.77 | 2019-2023 | Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.03 | 2023-2025 | Jardiance |
| Cvrx, INC. | $72.30 | 2022-2025 | Barostim Neo System |
| Esperion Therapeutics, INC. | $64.78 | 2023-2025 | Nexletol |
| Shockwave Medical, INC | $63.18 | 2025 | |
| Amarin Pharma, INC. | $38.62 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $35.99 | 2019 | |
| Philips North America LLC | $33.65 | 2022-2024 | (Ck7) Extended Holter |
| Baxter Healthcare | $24.78 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $23.66 | 2023 | Optimizer |
| Sanofi-Aventis U.S. LLC | $23.61 | 2019 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Infobionic, INC | $21.33 | 2024 | Mome Device |
| Actelion Pharmaceuticals US, INC. | $21.09 | 2019 | |
| G Medical Diagnostic Services, INC. | $20.45 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $19.78 | 2022 | |
| Abiomed | $19.35 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $15.93 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.79 | 2023 | Evkeeza |
| Allergan, INC. | $14.15 | 2019 | |
| Cardiovascular Systems INC. | $2.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Pacifico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.